While the drugs show moderate benefits, the ruling highlights the need for better diagnostic rates and long-term planning for future Alzheimer’s treatments
UK’s drug regulator gave the green light for the drug, but NICE rejected it as the benefits ‘are too small to justify the costs’
BJN provides nurses with an evidence base for clinical practice and a platform for professional development. It shares the information and advice that is key to unlocking your full potential.
Clinical expertise
Peer-reviewed research
Best practice guidance
CPD support
